September 27th, 2010
Xience V Holds Its Own With Sirolimus-Eluting Stents
Larry Husten, PHD
In the trials presented on Thursday at TCT, the everolimus-eluting Xience V stent (EES) proved superior to the paclitaxel-eluting Taxus stent at 2 years. But, as Gregg Stone discussed here recently, a more formidable comparator for EES are the sirolimus-eluting stents (SES). Two trials presented on Friday demonstrated that EES are comparable in efficacy to SES. […]
NEJM Journal Watch — Recent Cardiology Articles- More Data Support Semaglutide for Obesity-Related HFpEF, Regardless of Diabetes Diagnosis
- A Novel Agent Fails to Improve Outcomes in Diabetic Cardiomyopathy
- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?